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We compared children who were positive  for Ebola virus 
disease (EVD) with those who were negative to derive a 
pediatric EVD predictive (PEP) score. We collected data 
on all children <13 years of age admitted to 11 Ebola hold-
ing units in Sierra Leone during August 2014–March 2015 
and performed multivariable logistic regression. Among 
1,054 children, 309 (29%) were EVD positive and 697 
(66%) EVD negative, with 48 (5%) missing. Contact his-
tory, conjunctivitis, and age were the strongest positive 
predictors for EVD. The PEP score had an area under 
receiver operating characteristics curve of 0.80. A PEP 
score of 7/10 was 92% specific and 44% sensitive; 3/10 
was 30% specific, 94% sensitive. The PEP score could 
correctly classify 79%–90% of children and could be used 
to facilitate triage into risk categories, depending on the 
sensitivity or specificity required.
The Ebola virus disease (EVD) outbreak in West Af-rica claimed >11,000 lives with nearly 30,000 cases 
(1). During the outbreak in Sierra Leone, patients arriv-
ing at healthcare facilities were screened for EVD using 
World Health Organization (WHO) case definitions. Those 
fulfilling the case definition for suspected EVD were 
admitted to Ebola holding units (EHUs) to have blood taken 
for EVD testing and receive medical care until test results 
were available (online Technical Appendix Figure 1, 
https://wwwnc.cdc.gov/EID/article/24/2/17-1018-
Techapp1.pdf). Testing was usually performed offsite, with 
a turnaround time for results of ≈48 hours (2). During ad-
mission, however, EVD-negative patients risked exposure 
to EVD, raising concerns that EHUs could act as amplifica-
tion sites for infection (3–7). Children, many of whom were 
unaccompanied, were particularly vulnerable, and, because 
EHUs were overstretched, supervision to minimize the risk 
of cross-infection was challenging (4,8).
An accurate case definition for suspected EVD is criti-
cal for future outbreaks. Insufficient sensitivity of case defi-
nitions results in EVD-positive patients not being isolated, 
risking onward transmission in the community. There is 
an inherent tension between the public health priority to 
maximize the sensitivity of the case definition (minimiz-
ing onward transmission risk) and the individual patient’s 
perspective. The trade-off made by lower specificity means 
that many EVD-negative patients are kept waiting in EHUs 
for test results, risking nosocomial infection and delaying 
treatment for their true underlying condition. Case defini-
tions should be flexible because priorities may change as 
outbreaks progress. In the 2014–2015 epidemic, the pro-
portion of patients testing positive decreased over time: in 
October 2014, 77% of those admitted to a Freetown EHU 
tested positive, versus 1% in April 2015 (5).
In Sierra Leone, 2 case definitions were used for sus-
pected EVD (9). Until November 2014, most EHUs used a 
WHO case definition that was the same for both adults and 
children, defining anyone who had >3 symptoms consistent 
with EVD and fever, or who had fever and had contact with 
a person with EVD, as having a suspected case (early-2014 
case definition). Beginning in December 2014, the WHO 
Development of a Pediatric Ebola 
Predictive Score, Sierra Leone1
Felicity Fitzgerald,2 Kevin Wing,2 Asad Naveed, Musa Gbessay, J.C.G. Ross,  
Francesco Checchi, Daniel Youkee, Mohamed Boie Jalloh, David E. Baion, Ayeshatu Mustapha,  
Hawanatu Jah, Sandra Lako, Shefali Oza, Sabah Boufkhed, Reynold Feury, Julia Bielicki,  
Elizabeth Williamson, Diana M. Gibb, Nigel Klein, Foday Sahr, Shunmay Yeung
 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 2, February 2018 311
Author affiliations: University College London Great Ormond Street 
Institute of Child Health, London, UK (F. Fitzgerald, N. Klein); Save 
the Children, Freetown, Sierra Leone, and London (F. Fitzgerald, 
K. Wing, A. Naveed, M. Gbessay, J.C.G. Ross, F. Checchi); London 
School of Hygiene & Tropical Medicine, London (K. Wing,  
F. Checchi, S. Oza, S. Boufkhed, E. Williamson, S. Yeung); Kings 
Sierra Leone Partnership, Kings Centre for Global Health, Kings 
College London, London (D. Youkee); 34 Military Hospital, Republic 
of Sierra Leone Armed Forces, Freetown (M.B. Jalloh, F. Sahr); Ola 
During Children’s Hospital, Sierra Leone Ministry of Health, Free-
town (D.E. Baion, A. Mustapha); Cap Anamur (German  
Emergency Doctors), Ola During Children’s Hospital, Freetown  
(H. Jah); Welbodi Partnership, Ola During Children’s Hospital, 
Freetown (S. Lako); Western Area Emergency Response Centre, 
Freetown (R. Feury); MRC Clinical Trials Unit at UCL, London  
(J. Bielicki, D.M. Gibb); Farr Institute of Health Informatics, London 
(E. Williamson)
DOI: https://doi.org/10.3201/eid2402.171018
1Preliminary results from this study were presented at the 26th 
European Congress of Clinical Microbiology and Infectious 
Diseases, Amsterdam, Netherlands, April 9–12, 2016; and the 
34th Annual Meeting of the European Society for Pediatric 
Infectious Diseases, Brighton, UK, May 10–14, 2016.
2These authors contributed equally to this article.
RESEARCH
case definition was modified to be age dependent (late-2014 
case definition) (Figure 1; online Technical Appendix Table 
1). Under this definition, children only required fever and 
either 1 symptom (in children <5 years of age), 2 symptoms 
(in children 5–12 years of age), or >3 symptoms (in children 
>12 years of age) (4). This definition increased the likelihood 
of admitting EVD-negative children. Furthermore, in over-
stretched EHUs, children may have been admitted without 
meeting the criteria for suspected EVD, regardless of defini-
tion. In a mixed-age West African cohort, 9% of those ad-
mitted did not fulfill the early-2014 case definition (3).
We aimed to develop a predictive score that could be 
used to tailor the pediatric case definition for suspected EVD 
according to the clinical and epidemiologic setting. The goal 
was to potentially limit unnecessary admissions to EHUs for 
EVD-negative children without reducing sensitivity.
Methods
Data Sources
We collected data on all children <13 years of age admit-
ted to 11 EHUs in Sierra Leone (August 2014–March 2015) 
and built training and validation datasets. We performed 
multivariable logistic regression on the training dataset to 
generate a pediatric Ebola predictive (PEP) score, which we 
tested on the validation dataset. The age cutoff matched the 
WHO case definition distinguishing between children and 
adolescents, anticipating that adolescents would have an 
adult disease phenotype. Settings and data collection meth-
ods have been described previously (4,10). We visited each 
EHU to extract data from paper clinical records, case inves-
tigation forms, and site admission books and to interview 
staff. We cross-referenced data with the Western Area Ebola 
Response Centre (WAERC) database and 4 further sources, 
and single-entered data into a password-protected database 
(Epi Info version 7.1.4; US Centers for Disease Control and 
Prevention, Atlanta, GA, USA) (online Technical Appen-
dix). We removed personal identifiers before analysis and 
developed a schema for record matching across databases 
(online Technical Appendix). We obtained ethics approval 
for this study from the Sierra Leone Ethics and Scientific 
Review Committee and the London School of Hygiene and 
Tropical Medicine Ethics committee (reference 8924).
Statistical Analysis
We used Stata version 14.0 (StataCorp LLC, College Sta-
tion, TX, USA) to perform analyses and limited analysis 
to children with EVD laboratory test result data. Vari-
ables were sex, age, contact history (yes/no), presence of 
16 symptoms at EHU admission (yes/no), and days from 
symptom onset to EHU visit (4). We included age as a 
binary variable (<2 years and >2 years), given the higher 
burden of febrile illnesses that appear similar to EVD (e.g., 
malaria) in younger children. We considered data to be 
missing from the analysis if no value had been entered in 
the source documents (i.e., neither yes nor no).
Descriptive analysis of the cohort comprised the num-
ber of children with data available for each variable and the 
prevalence of signs and symptoms by laboratory-confirmed 
EVD status. We estimated the proportion of children (for 
whom we had sufficient data) who met the late-2014 WHO 
case definition.
Predictive Model Building and Validation  
and Development of Risk Score
We split the data randomly into 2 datasets with equiva-
lent proportions of laboratory-confirmed EVD-positive 
children: a training dataset for predictive score building, 
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Figure 1. World Health 
Organization screening 
flowchart for Ebola virus 
disease used during outbreak 
in Sierra Leone (late-2014 case 
definition). Adapted from (9).
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and a validation dataset to assess score performance (11). 
Using the training dataset, we calculated crude odds ratios 
(ORs) of association between potential predictive variables 
and outcome (laboratory-confirmed EVD status) and cre-
ated an initial multivariable model including all potential 
predictive variables. A final training model was obtained 
by removing variables with p>0.3 from the fully adjust-
ed model in a backward-stepwise fashion. The variables 
retained for constructing candidate PEP scores were age, 
gender, contact history, days from first symptoms to ad-
mission, and whether all symptoms were systematically 
documented (online Technical Appendix).
We created the PEP score by assigning integer scores 
to variables in the validation dataset on the basis of their 
regression coefficients in the training dataset model 
(score = 1 for coefficients <1, score = 2 for coefficients 
>1) (12). We calculated each child’s overall PEP score by 
adding together the integer scores for the variables present, 
which resulted in possible PEP scores of 0–10. To iden-
tify the most clinically useful PEP score, we computed the 
sensitivity, specificity, positive predictive value, negative 
predictive value, and percentage of children correctly clas-
sified (compared with the standard of laboratory confirma-
tion of EVD) of each candidate PEP score. Fully calculat-
ing the validity of the WHO case definition would require 
data on false negatives (those turned away at screening 
who had EVD), but these data were not available. We 
compared the PEP score with the WHO case definition as 
accurately as the available data permitted for completeness 
(online Technical Appendix).
To explore the potential effects of PEP scores on the 
number of correct and incorrect admissions at different 
times in the epidemic, we applied 2 PEP scores with dif-
ferent levels of sensitivity and specificity to 2 hypotheti-
cal populations of children: early in the epidemic when the 
proportion of suspected cases testing positive in Western 
EHUs was 77% (high background prevalence, October 
2014); and later in the epidemic when the proportion was 
4% (low background prevalence, March 2015). We used 
these hypothetical background prevalences with the sensi-
tivity and specificity for each score to calculate number of 
true positives and negatives and false positives and nega-
tives obtained by applying each score (online Technical 
Appendix Tables 2–5) (5). We used multiple imputation by 
chained equations to account for missing data in the anal-
ysis of training and validation datasets (online Technical 
Appendix) (13).
Results
Of 1,054 children admitted with suspected cases to 11 
EHUs during August 14, 2014–March 31, 2015, no result 
was available for 48 (5%) (online Technical Appendix). 
Of the remaining 1,006 children, 309 (31%) were EVD 
positive and 697 (69%) EVD negative. Admissions rose 
from a median 8 (interquartile range [IQR] 5–11) per week 
in August–October 2014 to 50 (40–58) per week in Febru-
ary–March 2015, but the proportion of children that were 
EVD positive decreased from 57% (95% CI 43%–72%) in 
October 2014 to 6% (95% CI 2%–9%) in February 2015. 
At Ola During Children’s Hospital (ODCH), the main chil-
dren’s hospital in Freetown, the onsite EHU received 59% 
of all EHU admissions, increasing from 12% in August–
October 2014 to 82% in February–March 2015. 
We documented admission of 211 (21%) unaccompa-
nied children. Data were missing for 297 (30%) of the chil-
dren. EVD-positive children were more likely to be unac-
companied than those who were EVD negative (p<0.001).
Median patient age was 4 years (IQR 1.3–8.0 years), 
and 51% of the children were female (Table 1). Contact 
with EVD was reported for 275 (36%) of 754 children who 
had data available (75% of 1,006 total). Median time from 
symptom onset to hospital visit was 2 days (IQR 1–4). Fe-
ver data were available for 787 (78%) of children (Table 1), 
775 of whom also had data available on the presence of >3 
other symptoms. For those with data, fatigue/weakness was 
most frequently reported (97%), followed by fever (94%), 
anorexia (80%), vomiting (61%), headache (62%), and 
diarrhea (46%) (Table 1). Bleeding was rare, reported by 
3%. Of the 809/1,006 (80%) of children who had sufficient 
symptom and contact history data recorded to ascertain if 
they fulfilled the late-2014 WHO suspected case definition, 
31 (4%) were admitted despite not meeting the definition 
(online Technical Appendix.).
Children who were EVD negative were younger (me-
dian age 3 years [IQR 1–7 years] vs. 6 years [IQR 3–10 
years]; p<0.001) (Table 1) and less likely to have conjunc-
tivitis (p<0.001) than those who were EVD positive. Rash 
was more common in EVD-negative children (p<0.001) 
(Table 1; Figure 2). Similar proportions of both groups re-
ceived antimicrobial and antimalarial drugs, and whereas 
both spent a median of 2 days in an EHU (admission to 
death or transfer/discharge), those with EVD tended to stay 
longer (p<0.001) (Table 1).
Randomly splitting the cohort of 1,006 children gener-
ated training and validation datasets of 504 and 502 (de-
scriptive, crude, and adjusted analysis in online Technical 
Appendix Table 6). In the training cohort, positive con-
tact (multivariable OR 9.1, 95% CI 4.9–17); age >2 years 
(multivariable OR 2.9, 95% CI 1.4–5.8); and conjunctivitis 
(multivariable OR 3.8, 95% CI 1.9–7.8) were the strongest 
positive predictors of EVD. Headache, difficulty breath-
ing, difficulty swallowing, and rash were negative predic-
tors. The final multivariable predictive model included 12 
variables: gender; age; positive contact; and presence or 
absence at hospital visit of fever, diarrhea, conjunctivitis, 
anorexia, abdominal pain, headache, difficulty breathing, 
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difficulty swallowing, and rash. We present only analysis 
of the complete records, based on the similarity of receiver 
operating characteristics (ROC) curves for imputed and 
complete records analyses (online Technical Appendix 
Table 7, Figure 3).
Assigning predictive model values derived from the 
training dataset to the validation dataset gave a range of 
PEP scores of 0–10. Plotting the ROC curve as sensitiv-
ity (x) against 1 − specificity (y) for all individual child 
PEP scores (with sensitivity and specificity calculated us-
ing the laboratory test as standard) demonstrated that the 
model had excellent discriminative ability (area under 
ROC curve = 0.80; Figure 3) (14). The model coefficients, 
p values, and assigned integer PEP scores are shown in 
Table 2 and the sensitivity, specificity, positive and nega-
tive predictive values, and percentage correctly classified 
for all possible PEP scores within the validation dataset 
in Table 3. A PEP score of 1 was 97% sensitive (95% CI 
89%–100%) and 4% specific (95% CI 1%–8%), whereas 
the maximum PEP of 10 was 5% sensitive (95% CI 1%–
13%) and 99% specific (95% CI 96%–100%) (Table 3).
We considered the effect of using different PEP scores 
at different times during the outbreak. PEP score 3 (sen-
sitivity of 94% and specificity of 30%) at the high back-
ground prevalence time point would have correctly classi-
fied 79 patients, with 16 EVD-negative patients admitted 
unnecessarily and 5 EVD-positive patients being incor-
rectly not admitted (Table 4; online Technical Appendix 
Tables 2, 3). Using a PEP score of 7 (sensitivity 44% and 
specificity 92%) at the low background prevalence time 
point would have correctly classified 90/100 patients, with 
8 unnecessary admissions and 2 true EVD-positive patients 
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Table 1. Overview of 1,006 children who attended an Ebola holding unit and had EVD test results recorded, by final EVD test result 
status, Sierra Leone, August 14, 2014–March 31, 2015* 
Characteristic  
All children,  
no. (%) or 
median (IQR) 
EVD negative 
 
EVD positive 
p value 
No./no. available 
or median (IQR) % (95% CI) 
No./no. available 
or median (IQR) % (95% CI) 
Total† 1,006 (100) 697 69  309 31 – 
Sex        
 F 512 (51) 348/697 50 (46–54)  164/309 47 (41–53) 0.357 
 M 494 (49) 349/697 50 (46-54)  145/309 53 (47–59) 0.380 
Median age, y (IQR) 4 (1.3–8) 3 (1–7) –  6 (3–10) – <0.001 
Age 0–2 y 392 (39) 336/697 48 (44–52)  56/309 18 (14–23) <0.001 
Positive contact, n = 754‡ 275 (36) 108/541 20 (17–24)  167/213 78 (72–84) <0.001 
Days from symptoms to EHU 
admission, n = 772 
2 (1–4) 2 (1–3) –  3 (2–4) – 0.001 
Admitted with caregiver, n = 822 822 (82) 516/621 83 (80–86)  127/201 63 (56–70) <0.001 
Signs/symptoms§        
 Fever, n = 787 740 (94) 528/566 93 (91–95)  212/221 96 (92–98) 0.160 
 Fatigue/weakness, n = 587 568 (97) 393/407 97 (94–98)  175/180 97 (94–99) 0.676 
 Vomiting/nausea, n = 777 472 (61) 345/556 62 (58–66)  127/221 57 (51–64) 0.238 
 Diarrhea, n = 763 351 (46) 252/548 46 (42–50)  99/215 46 (39–53) 0.988 
 Conjunctivitis, n = 669 152 (23) 73/463 16 (13–19)  79/206 38 (32–45) <0.001 
 Anorexia, n = 779 621 (80) 452/560 81 (77–84)  169/219 77 (71–83) 0.269 
 Abdominal pain, n = 594 269 (45) 155/392 40 (35–45)  114/202 56 (49–63) <0.001 
 Muscle pain, n = 577 212 (21) 127/377 34 (29–39)  85/200 43 (36–50) 0.037 
 Joint pain, n = 569 192 (34) 102/368 28 (23–33)  90/201 45 (38–52) <0.001 
 Headache, n = 598 370 (62) 256/397 65 (60–69)  114/201 57 (50–64) 0.065 
 Difficulty breathing, n = 738 199 (27) 169/533 32 (28–36)  30/205 15 (10–20) <0.001 
 Difficulty swallowing, n = 687 177 (26) 130/481 27 (23–31)  47/206 23 (17–29) 0.247 
 Rash, n = 728 98 (13) 88/522 17 (14–20)  10/206 5 (2–9) <0.001 
 Cough, n = 587 70 (12) 57/407 14 (11–18)  13/180 7 (4–12) 0.019 
 Hiccups, n = 723 62 (9) 52/519 10 (8–13)  10/204 5 (2–9) 0.027 
 Unexplained bleeding, n = 726 22 (3) 19/518 4 (2–6)  3/208 1 (0–4) 0.114 
Treatment¶        
 Antimicrobial drug, n = 657 556 (85) 407/494 82 (79–86)  149/163 91 (86–95) 0.006 
 Antimalarial drug, n = 657 567 (86) 416/494 84 (81–87)  151/163 93 (87–96) 0.007 
 IV treatment 115 (11) 101/697 14 (12–17)  14/309 5 (2–7) <0.001 
Malaria RDT+, n = 74 33 (45) 31/57 54 (41–68)  2/17 12 (15–36) 0.002 
Median days of EHU stay# 2 (1–3) 2 (1–2) –  2 (1–3) – <0.001 
*n values and denominators indicate no. children with recorded data available for variable (i.e., for binary variables children with neither “yes” nor “no” 
populated in their source notes were not included in the denominator, and for the median days symptoms to EHU admission variable those without date of 
start of symptoms were not included). EHU, Ebola holding unit; EVD, Ebola virus disease; RDT, rapid diagnostic test. 
†z-test of proportions, comparing whether the proportion of children with the variable was the same for EVD-negative and EVD-positive children (apart 
from numerical variables, for which a Wilcoxon rank-sum test was performed to test the hypothesis that the distribution of the variable was the same for 
EVD-negative and EVD-positive children).  
‡Total no. children admitted to holding units with test results available.  
§Recorded on presentation at EHU.  
¶At EHU.  
#Time from EHU admission until death, discharge, or transfer. 
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incorrectly not admitted (Table 4; online Technical Appen-
dix Tables 4, 5). Because we only have the true EVD status 
of patients who were admitted despite screening negative 
by WHO case definition (not the much larger number who 
were WHO case definition negatives and not admitted), 
the sensitivity and specificity calculated may be unreliable 
(online Technical Appendix). However, on the basis of the 
data available, the WHO case definition was estimated to 
be 98% sensitive and 5% specific (Table 3; online Techni-
cal Appendix Tables 8, 9).
Discussion
This large, multicenter study compared symptoms at hos-
pital visit in children <13 years old who were determined 
to be positive or negative for EVD during the outbreak 
in West Africa. As with many childhood diseases, EVD 
symptoms are nonspecific. The WHO indicators, including 
fever, breathing difficulties, and gastrointestinal symptoms, 
are common features in many pediatric pathologies. In this 
outbreak, gastrointestinal symptoms dominated, whereas 
bleeding, characteristic of previous outbreaks, was rare 
(3,15–19). This difference meant clinical diagnosis of EVD 
in the West African outbreak was difficult, which moti-
vated this study. The lack of specificity of both early- and 
late-2014 WHO case definitions is highlighted by the fact 
that 69% of the children admitted as suspected EVD cases 
in this cohort were uninfected; that number increased to 
94% in low-prevalence weeks (10).
Although elegant clinical predictive models have been 
developed for mixed-age cohorts, the focus of our model 
is children (3,17,18,20–22). The features at presentation 
that had the strongest association with a positive laboratory 
test result in this study were positive contact, conjunctivitis 
(similar to mixed-age cohorts [17,22]), and age >2 years. 
Fever, anorexia, abdominal pain, and diarrhea were weaker 
predictors of EVD. Certain features in the late-2014 WHO 
case definition were either not predictive or negative predic-
tors, including bleeding, vomiting/nausea, difficulty breath-
ing or swallowing, muscle or joint pain, headache, or rash 
(Table 1) (9). These findings emphasize the challenge of 
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Figure 2. Frequency of clinical 
features in children positive 
and negative for Ebola virus 
disease (unadjusted) at an 
Ebola holding unit, Sierra 
Leone, August 14, 2014–
March 31, 2015.
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diagnosing EVD against high background rates of malaria 
and respiratory and gastrointestinal infections in children. 
The early-2014 WHO case definition demonstrated similar 
lack of specificity (32%) in 1 retrospective mixed-age co-
hort (sensitivity 80%) (3), although slightly better figures 
were documented in 2 smaller mixed-age cohorts (20,23).
The PEP score model described here could provide the 
basis for modifying pediatric case definitions as an outbreak 
evolves, or for different pediatric populations (e.g., at tri-
age in an EHU vs. potentially lower-risk routine outpatient 
consultations). Similar to the mixed-age, malaria-sensitive 
score proposed by Hartley et al. (17), a patient with a high 
score would be strongly suspected and a low score weakly 
suspected of having EVD. In times of high community 
prevalence, children with a PEP score >7 (>92% specific-
ity, 44% sensitivity) could rapidly be transferred to an ETC 
while awaiting laboratory confirmation, whereas those with 
a PEP score of 3 (sensitivity 94%, specificity 30%) could 
await test results in the EHU. This change could hasten 
access to specialist care for children with EVD and reduce 
exposure risk for those who are negative.
Assessing the applicability of our PEP score to future 
Ebola virus epidemics is important. Ideally, the model 
should be tested against other datasets from West Africa 
and prospectively in future outbreaks, because different 
EVD strains are likely to result in different disease mani-
festations. Indeed, in another pediatric cohort from Kaila-
hun and Bo, Sierra Leone, containing 91 children <5 years 
of age, fever was absent in 25% (compared with 4% in our 
study) whereas bleeding was seen in 15% (15). In a large 
international cohort of 1,371 children <16 years of age with 
EVD, fever prevalence was 90% and bleeding 10% (24). 
However, it is possible that future pediatric case numbers 
may be smaller than those seen in this outbreak, which 
limits opportunities for prospective validation. We sug-
gest governmental and nongovernmental organizations use 
this non–outbreak period to discuss with local stakeholders 
the acceptability of the trade-offs inherent within the PEP 
score, such as public health versus individual risk. One op-
tion would be the rapid setup of a triage facility admitting 
children with a PEP score >3 to await test results and fast-
tracking those scoring >7 to specialized Ebola treatment. 
However, this decision is highly context-specific, and there 
are dangers in being too prescriptive without taking into 
account factors such as local healthcare-seeking behavior.
A key limitation to our study is that PEP scores are 
derived from a population of children admitted to EHUs, 
all of whom should have fulfilled either the early- or late-
2014 WHO suspected case definition. We do not have 
information on those not admitted (who were either truly 
EVD negative or missed EVD-positive cases). Therefore, 
we could only use data on the small number of children 
admitted who did not meet the WHO case definition to cal-
culate its sensitivity and specificity, and these children may 
not have been representative of children who were negative 
by the WHO case definition but not admitted. Our calcula-
tions of WHO case definition validity are therefore only in-
cluded for completeness and must be treated with caution. 
A further limitation is reducing EVD contact to a binary 
variable; more in-depth information (such as whether the 
child has had contact with a dead body, or whether the child 
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Figure 3. Receiver operating characteristics curve for final 
pediatric Ebola predictive score model based on a cohort of 
children who attended an Ebola holding unit and had Ebola virus 
disease test results recorded, Sierra Leone, August 14, 2014–
March 31, 2015.
 
Table 2. Scores for each of the variables included in Ebola pediatric predictive model 
Variable 
Coefficient (95% CI) from  
multivariable model  p value Integer score value 
Positive contact 2.21 (1.58–2.83) <0.001 +2 
Conjunctivitis 1.34 (0.62–2.05) <0.001 +2 
Age >2 y 1.06 (0.37–1.75) 0.003 +2 
Fever 0.99 (–0.66 to 2.63) 0.241 +1 
Anorexia 0.59 (–0.18 to 1.35) 0.133 +1 
Male gender 0.49 (–0.11 to 1.08) 0.111 +1 
Abdominal pain 0.42 (–0.23 to 1.08) 0.205 +1 
Diarrhea 0.40 (–0.21 to 1.01) 0.197 +1 
Difficulty breathing –0.57 (–1.39 to 0.24) 0.168 1 
Difficulty swallowing –0.59 (–1.39 to 0.19) 0.138 1 
Headache –0.63 (–1.29 to 0.35) 0.063 1 
Rash 1.00 (–2.13 to 0.14) 0.085 2 
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is breastfeeding) could give greater discrimination. How-
ever, because 37% EVD-positive children were unaccom-
panied at hospital admission, an in-depth contact history 
was unlikely to be reliable.
Missing and unreliable data are another limitation, 
illustrating the challenge of epidemiologic studies that 
analyze data from emergency settings. This study was 
retrospective, using data collected as part of outbreak 
data gathering rather than as part of a formal prospec-
tive study. We accounted for missing data using multiple 
imputation; reassuringly, imputed analysis gave similar 
results to a complete records analysis. We are also lim-
ited to data from those who sought medical care; thus, the 
description of EVD/non-EVD cases may be incomplete. 
External and prospective validation will be key but may 
be limited by small numbers. Finally, Hartley et al. have 
demonstrated the crucial importance of malaria testing 
in diagnostic screening for EVD (17). We did not have 
sufficient numbers of children with malaria test results 
in this cohort to incorporate malaria test results into our 
predictive score.
We have demonstrated that using a PEP score may 
help to streamline and improve management for children 
with suspected EVD, but the score still does not approach 
the accuracy of laboratory testing. Even by using a sen-
sitive PEP score of 3, at high background prevalence, it 
is possible that 6% (5/77) of children with EVD could be 
turned away from an EHU in error (Table 4), which would 
have serious public health implications. Several highly 
sensitive rapid diagnostic tests (RDT) for EVD underwent 
preliminary testing toward the end of the West Africa out-
break, although the numbers of children included in these 
studies were limited (25,26). Judicious use of EVD RDTs 
coupled with PCR tests to confirm results could have re-
duced the scale of the Sierra Leone outbreak (27). Further 
development of RDTs, and guidance on selecting the chil-
dren on whom to use them, is essential for preparing for 
and responding to future outbreaks. Incorporating screen-
ing criteria from an evidence-based clinical prediction 
model, such as this PEP score model, should contribute to 
this process.
In conclusion, this study compares features at hospital 
arrival in EVD-negative and EVD-positive children during 
the West African epidemic. We describe a predictive PEP 
score model that would allow for the selection of appro-
priate case definitions (prioritizing sensitivity or specific-
ity) depending on the clinical and epidemiologic setting. 
The selected PEP scores had higher positive and negative 
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Table 3. Validation of PEP score against a standard of laboratory-confirmed Ebola virus disease status, compared with WHO case 
definition, based on a cohort of children who attended an Ebola holding unit and had EVD test results recorded, Sierra Leone, August 
14, 2014–March 31, 2015* 
Score Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI) 
% Correctly classified 
(95% CI) 
0 100 1 (0–4) 31 (25–38) 100 31 (25–38) 
1 97 (89–100) 4 (1–8) 31 (25–38) 71 (29–96) 32 (26–39) 
2 97 (89–100) 13 (8–20) 33 (27–40) 91 (70–99) 39 (32–46) 
3 94 (85–98) 30 (22–37) 37 (30–45) 91 (79–98) 49 (42–56) 
4 86 (75–93) 49 (40–57) 43 (34–52) 89 (80–95) 60 (53–67) 
5 77 (64–86) 67 (58–74) 51 (40–61) 87 (79–92) 70 (63–76) 
6 58 (45–70) 82 (75–88) 59 (46–71) 81 (74–87) 75 (68–80) 
7 44 (31–57) 92 (86–96) 70 (54–83) 79 (72–85) 77 (71–82) 
8 23 (14–35) 95 (90–98) 68 (45–86) 74 (67–80) 73 (67–79) 
9 11 (5–21) 98 (94–100) 70 (35–93) 71 (64–77) 71 (64–77) 
10 5 (1–13) 99 (96–100) 75 (19–99) 70 (63–76) 70 (63–76) 
WHO case definition† 98 (95–99) 5 (3–7) 30 (27–34) 84 (66–95) 33 (29–36) 
*EVD, Ebola virus disease; NPV, negative predictive value; PEP, pediatric Ebola predictive; PPV, positive predictive value; WHO, World Health 
Organization. 
†Late-2014 WHO case definition with pediatric differentiations. 
 
 
Table 4. Comparison of 2 different PEP scores on a hypothetical population of 100 suspected EVD patients at different points in EVD 
outbreak with differing prevalence of EVD* 
PEP score 
October 2014, 77% of suspected EVD+ cases†  
 
March 2015, 4% of suspected EVD+ cases†  
True 
EVD+,  
correctly 
admitted 
True EVD–, 
correctly 
not 
admitted 
False  
EVD+, 
unnecessarily 
admitted 
False  
EVD–, 
incorrectly 
not admitted 
True 
EVD+, 
correctly 
admitted 
True EVD–, 
correctly 
not 
admitted 
False  
EVD+, 
unnecessarily 
admitted 
False 
EVD–, 
incorrectly 
not admitted 
3: 94% sensitivity, 
30% specificity 
72 7 16 5  4 28 68 0 
7: 44% sensitivity, 
92% specificity 
34 21 2 43  2 88 8 2 
*Laboratory-confirmed EVD status figures from Connaught Hospital (Freetown, Sierra Leone) during the 2014–2015 outbreak. EVD, Ebola virus disease; 
PEP, pediatric Ebola predictive; +, positive; –, negative.  
†True or false EVD+ or EVD– determined by case ascertainment by PEP score. Admission result represents modeled outcome for patients in terms of 
Ebola holding unit.  
 
RESEARCH
predictive values than the current WHO case definition. 
Applying the score in combination with RDTs could be a 
successful strategy in future outbreaks. External validation 
of the PEP score will be key to establishing its utility, but 
because data are scarce, we suggest local stakeholders use 
this postoutbreak period to reflect how the PEP score might 
best be used in their context.
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